Abstract
Objective Youth with type 2 diabetes have higher metformin treatment failure rates when compared with adults. Our objectives were to develop a population pharmacokinetic (PK) model for metformin in youth to examine current dosing strategies and to quantify the relationship between metformin PK and obesity in youth with type 2 diabetes.
Research Design and Methods We performed semi-intensive PK sampling in 50 youth less than 18 years with T2D on metformin. We measured metformin levels at pre-dose and at 1–2 and 3–6-hours after a supervised 1000 mg dose of immediate-release metformin. We used non-linear mixed effects modeling to develop a population PK model. Simulations were performed to estimate area under the 24-hour metformin concentration-time curve (AUC) values.
Results Mean age was 15.0 (standard deviation (SD) 1.6) years, 66% were male, mean body mass index (BMI), 35.9 (SD 6.8) kg/m2, and mean estimated glomerular filtration rate (eGFR), 114.7 (SD 22.6) mL/min/1.73m2. Estimated clearance increased by 3% (21.4% relative standard error (RSE)) for every 1 kg/m2 increase in body mass index (BMI), and by 6% (53.8% RSE) for every 10 mL/min/1.73m2 increase in eGFR. When comparing AUC estimates from our model with data from 236 adults on metformin, median AUC for youth was lower than for adults on 2,000 mg of metformin (18.47 mg*h/L vs. 27.49 mg*h/L). Simulations showed that in youth, higher doses of at least 2,550 mg and up to 3,000 mg daily were needed to achieve exposures similar to adults.
Conclusions Obesity is associated with increased metformin clearance and reduced AUC in youth and higher doses are needed to achieve comparable drug exposure to adults.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by NIDDK K23DK120932
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee/IRB of University of California, San Francisco gave ethical approval for this work
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Abstract edited to correct typographical errors.
Data Availability
All data produced in the present study are available upon reasonable request to the authors
